首页>投融资
大湾生物
B轮
Great Bay Bio Group is a high-tech company that develops blue-ocean biologics on a data-based platform. It has a long-standing biomedical R&D technology platform and a rich product development pipeline.In September 2022, Great Bay Bio completed USD 15M Pre-series B funding led by Tiger Jade Capital.In December 2021, Great Bay Bio completed USD 10M series A fundraising
基本信息
-
公司全称大湾生物有限公司
-
类型人工智能生物医药研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数不明确
-
地址10th Floor,Jiyou Bank Building,78 Des Voeux Road; HK; Telephone: +85231023232; Fax: +8676939018698;
-
联系电话0769 39018698
-
邮箱info@greatbay-bio.com
-
成立时间2019-04-10
投融资
-
2024-12-16B轮未透露泰欣资本香港科技园创投基金
-
2022-09-13PreB轮数亿人民币泰欣资本AEF大湾区创业基金Vectr Ventures
-
2022-09-13PreB轮超亿元人民币Vectr Ventures泰欣资本AEF大湾区创业基金
-
2021-12-01A轮近千万美元比邻星创投高瓴创投阿里巴巴香港创业者基金阿隆资本
-
2021-12-01A轮近千万美元比邻星创投高瓴资本阿隆资本阿里巴巴
-
2021-02-23未公开380万美元富德资本阿里巴巴香港创业者基金富德金融集团
-
2021-02-23未透露380万美元阿里巴巴富德金融集团富德资本
-
2020-01-06未公开250万美元未透露
-
2020-01-06未透露250万美元未透露
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司,通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336,这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法,旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞,并修复其检测光的能力,使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012